Challenges and perspectives for the treatment of giant cell arteritis
Early diagnosis and prompt initiation of treatment are crucial to avoid severe complications in giant cell arteritis (GCA). The European Alliance of Associations for Rheumatology (EULAR) recommendations for the use of imaging in large vessel vasculitis have helped better define the role of different techniques for diagnosing and monitoring the disease. Regarding the treatment, corticosteroids remain the standard, and tocilizumab is the preferred corticosteroid-sparing treatment. New corticosteroid-sparing treatments and "ultra-light" corticosteroid usage regimens are also under study and could represent valid therapeutic alternatives in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Revue medicale suisse - 20(2024), 865 vom: 13. März, Seite 537-540 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Défis et perspectives pour le traitement de l’artérite à cellules géantes |
|---|
| Beteiligte Personen: |
Schweri, Céline [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.53738/REVMED.2024.20.865.537 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369724593 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369724593 | ||
| 003 | DE-627 | ||
| 005 | 20240315234312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.53738/REVMED.2024.20.865.537 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369724593 | ||
| 035 | |a (NLM)38482759 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Schweri, Céline |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Challenges and perspectives for the treatment of giant cell arteritis |
| 246 | 3 | 3 | |a Défis et perspectives pour le traitement de l’artérite à cellules géantes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Early diagnosis and prompt initiation of treatment are crucial to avoid severe complications in giant cell arteritis (GCA). The European Alliance of Associations for Rheumatology (EULAR) recommendations for the use of imaging in large vessel vasculitis have helped better define the role of different techniques for diagnosing and monitoring the disease. Regarding the treatment, corticosteroids remain the standard, and tocilizumab is the preferred corticosteroid-sparing treatment. New corticosteroid-sparing treatments and "ultra-light" corticosteroid usage regimens are also under study and could represent valid therapeutic alternatives in the future | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Iudici, Michele |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale suisse |d 2005 |g 20(2024), 865 vom: 13. März, Seite 537-540 |w (DE-627)NLM154244252 |x 1660-9379 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:865 |g day:13 |g month:03 |g pages:537-540 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.53738/REVMED.2024.20.865.537 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 865 |b 13 |c 03 |h 537-540 | ||